Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1979 5
1980 3
1981 2
1982 2
1983 1
1984 1
1987 2
1988 1
1990 1
1991 1
1992 1
1993 1
1994 1
1996 1
1997 3
1998 1
1999 2
2000 5
2001 4
2002 4
2003 6
2004 3
2005 8
2006 4
2007 11
2008 11
2009 5
2010 12
2011 13
2012 16
2013 11
2014 6
2015 7
2016 10
2017 12
2018 22
2019 29
2020 20
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 22594963

232 results
Results by year
Filters applied: . Clear all
Page 1
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V. De Petrocellis L, et al. Br J Pharmacol. 2013 Jan;168(1):79-102. doi: 10.1111/j.1476-5381.2012.02027.x. Br J Pharmacol. 2013. PMID: 22594963 Free PMC article.
Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J. Wang Y, et al. Prostate. 2015 Aug 1;75(11):1187-96. doi: 10.1002/pros.23000. Epub 2015 Apr 20. Prostate. 2015. PMID: 25894097
Towards the use of non-psychoactive cannabinoids for prostate cancer.
Pacher P. Pacher P. Br J Pharmacol. 2013 Jan;168(1):76-8. doi: 10.1111/j.1476-5381.2012.02121.x. Br J Pharmacol. 2013. PMID: 22849856 Free PMC article.
Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS. Thomas C, et al. Prostate. 2012 Jun 1;72(8):875-85. doi: 10.1002/pros.21490. Epub 2011 Oct 5. Prostate. 2012. PMID: 22072572
Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L, Giocanti N, Hennequin C, Favaudon V. Quéro L, et al. Prostate. 2010 Mar 1;70(4):401-11. doi: 10.1002/pros.21074. Prostate. 2010. PMID: 19902473
Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
Zhang Y, Won SH, Jiang C, Lee HJ, Jeong SJ, Lee EO, Zhang J, Ye M, Kim SH, Lü J. Zhang Y, et al. Pharm Res. 2012 Jun;29(6):1595-608. doi: 10.1007/s11095-012-0670-3. Epub 2012 Jan 27. Pharm Res. 2012. PMID: 22281759
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Culig Z, et al. Br J Cancer. 1999 Sep;81(2):242-51. doi: 10.1038/sj.bjc.6690684. Br J Cancer. 1999. PMID: 10496349 Free PMC article.
Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J, Lukesová M, Hlobilková A, Riháková P, Murray PG, Student V, Vojtsek B, Kolár Z. Madarová J, et al. Neoplasma. 2001;48(5):419-24. Neoplasma. 2001. PMID: 11845989
5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C. Gravina GL, et al. Prostate. 2010 Aug;70(11):1166-78. doi: 10.1002/pros.21151. Prostate. 2010. PMID: 20333699
Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.
Danquah M, Duke CB 3rd, Patil R, Miller DD, Mahato RI. Danquah M, et al. Pharm Res. 2012 Aug;29(8):2079-91. doi: 10.1007/s11095-012-0737-1. Epub 2012 Mar 27. Pharm Res. 2012. PMID: 22451249
232 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback